Age is no factor in TAVI

Adrichem, Rik; Mieghem, Nicolas Van

doi:10.1007/s12471-022-01725-4

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two widely used surgical risk scores in TAVR, the STS score and EuroSCORE II, incorporate age as a factor, and surgical risk increases with advancing age [21]. However, the effects of age on clinical outcomes vary among Western studies [17]. In an analysis evaluating the influence of age on TAVR outcomes based on data from the Swiss TAVI Registry, which included 7097 patients divided into four age groups: <70 years (n = 324, mean age 64.6 ± 5.8 and STS score 3.5 ± 4.1), 70-79 years (n = 1913, mean age 76.5 ± 2.6 and STS score 4.0 ± 3.7), 80-89 years (n = 4353, mean age 84.5 ± 2.7 and STS score 5.6 ± 4.0), and ≥90 years (n=507, mean age 92.0 ± 1.7 and STS score 8.2 ± 4.7), all-cause mortality, stroke, and permanent pacemaker implantation significantly increased with age (all P < 0.05), whereas other major outcomes according to VARC-2 showed no differences.…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, the number of patients undergoing TAVR for severe AS is increasing, and the average patient age is approximately 80 years [11,12]. The effects of advanced age on the clinical outcomes of TAVR patients are inconsistent, on the basis of various registry analyses and population studies across Europe and the United States [13][14][15][16][17]. Most of those studies involved patients with high surgical risk, thus potentially resulting in poorer clinical outcomes than might occur in patients with intermediate surgical risk [17].…”

Section: Introductionmentioning

confidence: 99%

“…The effects of advanced age on the clinical outcomes of TAVR patients are inconsistent, on the basis of various registry analyses and population studies across Europe and the United States [13][14][15][16][17]. Most of those studies involved patients with high surgical risk, thus potentially resulting in poorer clinical outcomes than might occur in patients with intermediate surgical risk [17]. However, some analyses have suggested, that compared with the Western population, the population of patients with aortic stenosis in Asia has a higher prevalence of bicuspid aortic valve (BAV) and a smaller aortic annulus size [18,19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Nguyen,

Van Nguyen,

et al. 2024

CVIA

View full text Add to dashboard Cite

Objectives: The increasing number of elderly patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement (TAVR) has prompted concerns regarding their clinical outcomes compared with the younger population. This study evaluated the outcomes of TAVR on the basis of age group (<80 or ≥80 years) among Vietnamese patients with severe aortic valve stenosis at intermediate surgical risk. Methods: From March 2017 to December 2022, 21 patients ≥80 years of age and 69 patients <80 years of age underwent TAVI at a single center. Clinical characteristics, procedures, and outcomes at 30 days and 1 year were compared with the Valve Academic Research Consortium (VARC-2) criteria. Results: Patients ≥80 years of age had a higher prevalence of comorbidities but no significant differences in other clinical characteristics and procedures. No statistically significant differences were observed in procedural mortality (4.8% vs. 0.0%, P = 0.233), 30-day mortality (5.0% vs. 1.5%, P = 0.405), and 1-year mortality (11.8% vs. 3.7%, P = 0.241) between age groups. Major endpoints at specified time points also showed no significant differences. Conclusions: TAVR in patients with aortic stenosis at intermediate surgical risk has similar clinical outcomes at 30 days and 1 year, according to VARC-2 criteria, with no statistically significant age-associated differences (≥80 vs. <80 years). However, further studies with larger patient populations are needed to better understand the effects of age on TAVI outcomes in patients with similar characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Nguyen,

Van Nguyen,

et al. 2024

CVIA

View full text Add to dashboard Cite

show abstract

“…Still, it noted that after 90 years of age, patients who underwent TAVI had similar mortality to a national reference population [47]. Age should not be the sole deciding factor when treating patients with AS; other factors, such as comorbidities and frailty, should also be considered [48]. TAVI may be appropriate for fully selected nonagenarians [42, 46, 49].…”

Section: Discussionmentioning

confidence: 99%

Patterns of Aortic Valve Replacement in Europe: Adoption by Age

Rudolph,

Appleby,

Delgado

et al. 2023

Cardiology

View full text Add to dashboard Cite

Introduction: The management of patients with severe aortic stenosis may differ according to patients’ age. The aim of this analysis was to describe patterns of aortic valve replacement (AVR) use in European countries stratified by age. Methods: Procedure volume data for AVR, including surgical aortic valve replacement (sAVR) and transcatheter aortic valve implantation (TAVI), for the years 2015–2020 were obtained from national databases for twelve European countries (Austria, the Czech Republic, Denmark, England, Finland, France, Germany, Norway, Poland, Spain, Sweden, and Switzerland). Procedure volumes were reported by patient age (<50 years, 5-year age groups between 50 and 85 years, and ≥85 years). Patients per million (PPM) population undergoing AVR each year were calculated using population estimates from Eurostat. Results: AVR PPM varied widely between countries, from 508 PPM in Germany to 174 PPM in Poland in 2020. TAVI rates ranged from 61% in Switzerland and Finland to 25% in Poland. AVR PPM increased with age to a peak at 80–84 years, after which it decreased again. AVR procedures increased from 2015 to 2019 at an average annual rate of 3.9%. AVR increased more substantially in people aged ≥80 years than in younger age groups; these older age groups accounted for 30% of all AVR procedures in 2015 and 35% in 2019. TAVI accounted for an increasing proportion of all AVR procedures as patient age increased; an overall average of 96% of males and 98% of females aged ≥85 years received TAVI as the treatment modality, although adoption of TAVI differed between countries. Conclusions: There is considerable variation in the rates of AVR use and the adoption of TAVI versus sAVR between European countries. The use of TAVI has increased in recent years, particularly for older patients.

show abstract

Age is no factor in TAVI

Cited by 2 publications

References 12 publications

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Patterns of Aortic Valve Replacement in Europe: Adoption by Age

Contact Info

Product

Resources

About